New drug may boost stem cell harvest for sickle cell gene therapy

NCT ID NCT06442761

Recruiting now Knowledge-focused Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether the drug motixafortide is safe for people with sickle cell disease and whether it can increase the number of stem cells that can be collected from their blood. These stem cells could be used in future gene therapies or transplants. The study involves 15 adults with severe sickle cell disease and aims to find the best dosing plan for larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch
RECRUITING

Bethesda, Maryland, 20814, United States
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States

Contact Email: •••••@•••••
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.